Evidence map›Paper›PMID 38687412›Full record

ArticleInternational journal of hematology2024

Clinical features of immature leukemias in children.

Daichi Sajiki, Nao Yoshida, Hideki Muramatsu, Kimiyoshi Sakaguchi, Naoko Maeda, Norifumi Yokoyama, Yuji Miyajima, Makito Tanaka, Yoshiyuki Takahashi, Asahito Hama

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daichi SajikiDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID http://orcid.org/0000-0003-4262-683X
Nao YoshidaDepartment of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital, 3-35 Michishita-Cho, Nakamura-Ku, Nagoya, 453-8511, Japan.
Hideki MuramatsuDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kimiyoshi SakaguchiDepartment of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Naoko MaedaDepartment of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Norifumi YokoyamaDepartment of Pediatric Hematology, Gifu Municipal Hospital, Gifu, Japan.
Yuji MiyajimaDepartment of Pediatrics, Anjo Kosei Hospital, Anjo, Japan.
Makito TanakaDepartment of Pediatrics, Fujita Health University School of Medicine, Toyoake, Japan.
Yoshiyuki TakahashiDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Asahito HamaDepartment of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital, 3-35 Michishita-Cho, Nakamura-Ku, Nagoya, 453-8511, Japan. hamaasahito@outlook.jp.ORCID http://orcid.org/0000-0002-7582-0201

Funding

Japanese Red Cross Aichi Medical Center Nagoya First Hospital Research Grant NFRCH22-0016
6 · The paper itself

Abstract

Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL), mixed phenotypic acute leukemia (MPAL), and acute myeloid leukemia with minimal differentiation (AML-M0) all originate from immature hematopoietic progenitor cells and have a poor prognosis. We investigated the clinical characteristics of these immature leukemias in 17 children (ETP-ALL: 8, MPAL: 5, AML-M0: 4) at seven institutions. Clinical and laboratory findings were comparable across disease types. Eleven and six patients received ALL- and AML-oriented induction chemotherapy, with six and four achieving complete remission (CR), respectively. Five additional patients achieved CR after salvage with the other type of chemotherapy. Eight patients received hematopoietic cell transplantation (HCT) in first CR, and six survived without relapse. However, six of seven patients who did not receive HCT during first CR relapsed; all underwent HCT later, and only three survived. The 5-year event-free survival (EFS) and overall survival (OS) rate were 37% and 69%, respectively. Patients who achieved CR after induction chemotherapy and received HCT in first CR had favorable EFS and OS. Notably, all patients who received HCT in first CR survived 5 years after diagnosis. Appropriate induction chemotherapy and HCT in first CR could improve the outcome of immature leukemias.

Indexed as

Hematopoietic Stem Cell TransplantationInduction ChemotherapyAdolescentChildChild, PreschoolDisease-Free SurvivalFemaleHumansInfantLeukemia, Myeloid, AcuteMalePrecursor T-Cell Lymphoblastic Leukemia-LymphomaPrognosisRemission InductionRetrospective StudiesSurvival RateAcute myeloid leukemia with minimal differentiationChildrenEarly T-cell precursor acute lymphoblastic leukemiaImmature leukemiasMixed phenotypic acute leukemia

Identifiers

PMID38687412

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.